Imphal News Flash

Alopecia Areata Market

DelveInsight has launched a new report on “Alopecia Areata – Market Insights, Epidemiology, and Market Forecast-2032”.

DelveInsight’s “Alopecia Areata – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Breakthroughs in the Alopecia Areata Market:

• The FDA has authorized Olumiant (baricitinib) oral tablets for the treatment of severe alopecia areata in adults, a condition characterized by patchy baldness and impacting over 300,000 individuals annually in the U.S. This recent decision represents the initial approval by the FDA of a systemic remedy, which addresses the entire body rather than a particular area, for alopecia areata.
• FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

Some of the key facts of the Alopecia Areata Market Report:

Alopecia areata is a common, clinically heterogeneous, immune-mediated, non-scarring hair loss disorder. The disease may be limited to one or more discrete, well-circumscribed round or oval patches of hair loss on the scalp or body, or it may affect the entire scalp (alopecia totalis) or the entire body (alopecia universalis). The onset can be at any age, but most people get it in their teens, twenties, or thirties. When it occurs in children younger than age 10, it tends to be more extensive and progressive.

• In 2022, the total prevalent cases of alopecia areata were ~704,000 in the US, which are expected to increase by 2032.
• As per Delveinsight, the total diagnosed cases of alopecia areata in the US were ~435,000 in 2022.
• According to the NIH, females and males are equally affected by Alopecia Areata

Key benefits of the Alopecia Areata market report:

1. Alopecia Areata market report covers a descriptive overview and comprehensive insight of the Alopecia Areata Epidemiology and Alopecia Areata  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Alopecia Areata market report provides insights on the current and emerging therapies.
3. Alopecia Areata market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Alopecia Areata market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alopecia Areata market.

Got queries? Click here to know more about the Alopecia Areata Market Landscape.

Alopecia Areata Overview

Alopecia Areata is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times on other areas of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), which results in the seizing of the hair growth stage. Hair follicles remain alive, and hair can regrow at any time in Alopecia Areata. Alopecia Areata usually begins with one or more patches which may be small, round, smooth on the scalp that can progress to total scalp hair loss or complete body hair loss. Genetic predisposition and environmental factors increase the chances of developing Alopecia Areata. 

Alopecia Areata Symptoms

Alopecia areata is a condition that primarily affects the hair. Its symptoms typically include:

• Patchy Hair Loss: The most common symptom is sudden hair loss in small, round patches on the scalp. These patches may overlap and can progress to total baldness in some cases.
• Hair Thinning: Hair may become thinner, fragile, or break easily.
• Complete Hair Loss: In more severe cases, the condition can result in complete loss of scalp hair (alopecia totalis) or loss of all body hair (alopecia universalis).
• Changes in Nail Texture: Some individuals may notice changes in the texture, shape, or thickness of their fingernails or toenails, such as pitting or roughness.
• Itching or Discomfort: Rarely, individuals may experience itching or discomfort in areas where hair loss occurs.

Alopecia Areata Market 

The dynamics of the Alopecia Areata market is anticipated to change in the coming years owing to the expected launch of emerging therapies by pharma players such as Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly and Company/Incyte Corporation, Alcaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, and others during the forecasted period 2019-2032.

Learn more by requesting for sample @ Alopecia Areata Market Landscape

Alopecia Areata Pipeline Therapies and Key Companies 

1. PF-06651600: Pfizer
2. Jaktinib: Suzhou Zelgen Biopharmaceuticals
3. Baricitinib: Eli Lilly and Company/Incyte Corporation
4. ATI-502: Alcaris Therapeutics 
5. LH-8: Legacy Healthcare 
6. CTP-543: Concert Pharmaceuticals

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Alopecia Areata Patient Share (%) Overview at a Glance

5. Alopecia Areata Market Overview at a Glance

6. Alopecia Areata Disease Background and Overview

7. Alopecia Areata Epidemiology and Patient Population

8. Country-Specific Patient Population of Alopecia Areata 

9. Alopecia Areata Current Treatment and Medical Practices

10. Unmet Needs

11. Alopecia Areata Emerging Therapies

12. Alopecia Areata Market Outlook

13. Country-Wise Alopecia Areata Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Alopecia Areata Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Alopecia Areata Market Outlook 2032. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services